Key Highlights

  • Azenta (NASDAQ:AZTA) closed up 20.80% on November 11, 2026, after reporting fiscal fourth quarter results on November 10.
  • Revenue rose 5% to USD 167 million and adjusted Earnings reached USD 0.28 per share against USD 0.21 a year earlier.
  • Fiscal 2027 Revenue guidance is USD 648 million to USD 660 million, with organic growth of 3% to 5% and adjusted EBITDA Margin up 200 to 250 basis points.
  • Azenta held about USD 506 million of cash and securities at year end and has USD 131.8 million left on a USD 250 million buyback program.

The Quarter and the Year

Azenta supplies sample management and genomics services to life science researchers and drug developers. In the fiscal fourth quarter, ended September 30, 2026, revenue rose 5% to USD 167 million, with organic growth of 2%. Sample management solutions revenue rose 9% to USD 94 million, led by repository services and consumables, while multiomics revenue was flat at USD 73 million as weaker sequencing services were offset by gene synthesis. Adjusted EBITDA margin was 11.6%, down from 13.0%, because of Fixed Cost absorption, quality remediation in automated stores and higher inventory reserves, although gross margin rose to 46.0%. For the full fiscal year, revenue rose 5% to USD 622 million and the company recorded a non-cash Goodwill Impairment of USD 149 million, which drove a large GAAP loss. Free Cash Flow was USD 27 million, and Operating Cash Flow was USD 58 million. Adjusted EBITDA for the year was USD 58.3 million, a 9.4% margin, down from 11.2% the year before, which is why investors focused so heavily on the outlook for improvement.

Why the Outlook Lifted the Stock

The shares reacted to the outlook, not the past year. Management guided fiscal 2027 revenue to USD 648 million to USD 660 million, above expectations, with organic growth of 3% to 5% and a margin improvement of 200 to 250 basis points, including about 100 points of dilution from two recent acquisitions, Elegen and SynPlexity. Free cash flow is expected to rise about 25%, and first quarter organic growth is guided to 3% to 4%. Shares of Azenta (NASDAQ:AZTA) rose 20.8%, as the guidance suggested that margins are turning after a difficult year. The interim chief executive said the company closed fiscal 2026 with improving momentum and that fiscal 2027 is about consistent execution and accelerating performance. The company has also returned capital, repurchasing USD 118.2 million of stock during the year, and it sold its B Medical Systems Business on July 1, 2026, simplifying the portfolio.

Risks Behind the Rally

Execution remains the central question. Margins fell in the fourth quarter, and quality problems in the automated stores business must be resolved before profitability improves. The company is led by an interim chief executive, so a permanent appointment could change strategy. Acquisitions add integration risk, and the Elegen license carries fixed payments of USD 23.0 million over five years. Demand from academic and biotech customers depends on research funding and Capital markets, which are sensitive to interest rates, with a December Federal Reserve hike priced. Investors will watch first quarter margins, progress on the multiomics business and any news on leadership, along with buybacks, to judge whether the outlook is credible after a sharp one-day rerating. The UK Biocentre Acquisition also added about three points to fourth quarter growth, so organic trends, which were weaker, deserve as much attention as the reported figures.

Where Things Stand

Azenta (NASDAQ:AZTA) rose 20.8% on November 11, 2026 after guiding fiscal 2027 revenue to USD 648 million to USD 660 million with a 200 to 250 basis point margin improvement. Fourth quarter revenue was USD 167 million. Margin recovery, acquisition integration and a Leadership change remain the main risks.